Isabelle Lepage-Nefkens is a partner at Panaxea, an Amsterdam-based independent health care research organization dedicated to improving the application of evidence throughout the health care system. Isabelle Lepage- Nefkens holds master degrees in Bio-engineering (KULeuven, Belgium, 1999) and Public Health (NUS, Singapore, 2009) and a Ph.D. in Biology (Johannes Gutenberg Universtity, Germany, 2003). She developed a strong research background in molecular biology, infectious diseases, neurobiology and gene technology and Health Services Research in various global assignments including USA, Germany, Hong Kong and Singapore. In Singapore, she headed the R&D virology team of a biotech company in the pre-clinical drug development for hepatitis C and influenza. Since 2009, Isabelle provides consultancy services in health care to governmental organizations, biotech and pharmaceutical firms, covering aspects such as health services organization and management, health policy and strategy, health economics and market access.
MEET ISABELLE LEPAGE-NEFKENS AT #KFG2018
Isabelle Lepage-Nefkes will give a presentation in the session "TEST New Life Sciences Solutions":
'Early HTA as a tool to guide clinical development'
In an area where there is growing pressure on health care resources, showing positive efficacy and safety data is not sufficient anymore to ensure market access and adaptation of a medical innovation. HTA is a regulatory requirement for pharmaceuticals for reimbursement evaluations after market authorization. However, incorporating HTA much earlier in the R&D process of both pharmaceuticals and medical devise alike can steer value-driven drug development. Early HTA/health economic models can guide decisions by developers regarding efficient resource allocation, improved clinical development design and pricing decisions. The talk will show some of the advantages and challenges of building health economics into their early (clinical) development processes.